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There are unpredictable inter-individual di¡erences in
response to ultraviolet radiation, used in the treatment
of psoriasis and other common skin diseases. It is there-
fore essential that we attempt to identify phenotypic
markers that correlate with individual treatment out-
comes. Exposure of human skin to ultraviolet radiation
results in the generation of reactive intermediates and
oxidative stress. Hepatic drug metabolizing and cyto-
protective genes are induced as an adaptive response to
xenobiotics and reactive intermediates; as several of
these genes are present in skin, we hypothesized that
their cutaneous expression and regulation may be im-
plicated in responses to ultraviolet radiation. We used
quantitative real-time reverse transcription^polymerase
chain reaction to investigate interindividual di¡erences
in the cutaneous expression of a variety of drug meta-
bolizing and cytoprotective genes, including cyto-
chrome P450s, glutathione S-transferases and drug
transporters, and investigated the regulation of gene ex-
pression by ultraviolet radiation and in lesional psoriatic
skin. We con¢rmed signi¢cant induction of cyclooxy-
genase 2 (mean 3.63-fold, range 0.14^22.6, po0.0001) by
ultraviolet radiation and showed more modest (E2-
fold) inductions of glutathione peroxidase, and novel
inductions of glutathione S-transferase P1 and the drug
transporter multidrug resistance associated protein-1.
Glutathione S-transferase P1 (3.74-fold, 1.3^33.1, po
0.0001) and multidrug resistance associated protein-1
(4.06-fold, 1.3^24.8, po0.0001) were also signi¢cantly in-
creased in psoriatic plaque, as were P450 CYP2E1 (3.64-
fold, 1^28.9 po0.0001) and heme oxygenase-1 (10.19-
fold, 2.9^49.7, po0.0001), implying a di¡erential adaptive
response to oxidant exposure in lesional psoriatic skin.
We found considerable interindividual variation in con-
stitutive gene expression and inducibility, indicating
that these genes may be associated with individuality
in response to ultraviolet radiation. Key words: adenosine
triphosphate-binding cassette transporters/cytochrome P450/
gene expression pro¢ling/reverse transcription^polymerase
chain reaction/skin. J Invest Dermatol 121:390 ^398, 2003
T
here are unpredictable interindividual di¡erences in
sensitivity and response to photo(chemo)therapy in
patients with psoriasis (Green et al, 1992; Ibbotson
and Farr, 1999). It is therefore essential that we at-
tempt to identify phenotypic markers that may be
associated with the response of individual patients to ultraviolet
radiation (UVR), as ultimately this may enable prediction of
treatment outcomes.
Hepatic drug metabolizing enzymes and cytoprotective genes
are known to be important determinants of systemic drug hand-
ling and defense against reactive oxygen species (ROS), and have
been extensively studied in human liver and in rodent and cell
culture models. Individuality in the hepatic expression of drug
metabolizing enzymes has previously been shown to contribute
to interindividual di¡erences in response to drugs, environmental
toxins, and ROS (Wolf and Smith, 1999;Wolf et al, 2000). In ad-
dition to their role in classical ‘‘drug metabolism’’, many of these
genes are regulated as an adaptive response to environmental
challenge (Nebert, 2000). For example, ultraviolet radiation
(UVR) and psoralen UVA (PUVA) are both known to induce
oxidative stress and generate ROS (Mukhtar and Elmets, 1996)
and inheritance of speci¢c loss of function alleles of, for example,
the glutathione S-transferases (GST) has been associated with UV
sensitivity and increased susceptibility to skin cancer (Kerb et al,
1997, 2002; Lear et al, 2000). Human skin is the largest organ of
the body and the ¢rst line of defense against environmental in-
sult. It therefore seems logical that it would be a rich source of
drug metabolizing and cytoprotective genes; however, relatively
little is known about the expression and regulation of these genes
in human skin.
Cytochrome P450s (P450) are a multigene family of monoox-
ygenase enzymes, which, together with their redox partner
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NADPH P450 reductase (CPR), catalyze the oxidative metabolism
of the vast majority of drugs and xenobiotics to which we are ex-
posed (Gibson and Skett, 2001). P450 in subfamilies CYP1 to
CYP4 are responsible for the majority of foreign compound meta-
bolism, have unique but overlapping substrate speci¢cities and, in
general, are regulated by substrate-induced activation of gene tran-
scription (Gonzalez et al, 1993). P450 expression is highest in the
liver, but there is increasing evidence that many P450s are also ex-
pressed at signi¢cant levels in extrahepatic tissues (Tanaka, 1998).
There is marked interindividual variation in the expression and
activity of many hepatic P450s, which has been correlated with
treatment outcomes (Wolf and Smith, 1999;Wolf et al, 2000).
Cutaneous P450 expression, measured as aryl hydrocarbon hy-
droxylase activity, has been shown to be inducible following the
topical application of crude coal tar, a rich source of polycyclic
aromatic hydrocarbons, known to be potent inducers of P450
CYP1A1 (formerly aryl hydrocarbon hydroxylase) gene tran-
scription (Bickers and Kappas, 1978; Lawrence et al, 1984). Consti-
tutive expression of CYP1A1, and the closely related isozyme
CYP1B1, in human keratinocytes was recently con¢rmed in a ser-
ies of reverse transcription^polymerase chain reaction (reverse
transcription^PCR) experiments, which also identi¢ed mRNAs
encoding CYP2B6, CYP2E1, and CYP3A5, and demonstrated
CYP1A1 induction following benzanthracene treatment (Baron
et al, 2001). In a complementary study, mRNAs encoding P450
CYP2A6, CYP2B6, and CYP3A4 were identi¢ed in primary hu-
man keratinocytes using RNase protection analysis (Janmo-
hamed et al, 2001). Interestingly, recent data suggest that UVB
irradiation can induce the cutaneous expression of CYP1A1,
CYP1B1 (Katiyar et al, 2000), and CYP4A11 (Gonzalez et al,
2001), and we have recently shown that a novel P450, CYP2S1, is
expressed in human skin, and is inducible by both UVR, PUVA
and topical chemicals used to treat psoriasis (Smith et al, 2003).
Solar and arti¢cial UVR irradiation generate cytotoxic ROS
(Mukhtar and Elmets, 1996). As an adaptive response to repeated
UVR exposure, the cutaneous expression of antioxidant enzymes,
including superoxide dismutase and catalase, is induced in order to
neutralize ROS and protect the cell from oxidative stress (Mewes
et al, 2001). One of the most important cellular antioxidants is glu-
tathione, which is responsible for a number of free radical quench-
ing reactions (Tyrrell et al, 1991) and is an essential cofactor, for
example, for the antioxidant glutathione peroxidase (GPx)
enzymes. Glutathione can also be conjugated to reactive electrophi-
lic species, frequently produced in P450-mediated reactions, by
GSTs. The GSTs are also a multigene family of enzymes with
diverse substrate speci¢cities (Hayes and Strange, 2000). Speci¢c
GSTs, including GSTP1 (Del Boccio et al, 1987) and GSTA4
(Desmots et al, 2001) have been identi¢ed in human skin.
An additional cellular detoxi¢cation mechanism involves the
active e¥ux of toxins from the cell, catalyzed by a family of
ABC (adenosine triphosphate binding cassette) transporter pro-
teins. The expression of several ABC transporters, including the
multidrug resistance-associated protein 1 (MRP1), has recently
been reported in human keratinocytes (Baron et al, 2001). Human
skin is known to express a number of cytoprotective genes, in-
cluding cyclooxygenase-2 (COX-2, Leong et al, 1996) and heme
oxygenase-1 (HO-1, Applegate et al, 1995). COX-2, the rate-lim-
iting enzyme in the production of prostaglandins from arachido-
nic acid, is inducible by a number of in£ammatory stimuli,
including UVR (Buckman et al, 1998), whereas HO-1 catalyzes
the rate-limiting step in heme catabolism and is a key determi-
nant of cellular iron homeostasis (Tenhunen et al, 1968). HO-1
mRNA expression is known to be induced by cellular stresses,
including free radical ROS and UVA (Applegate et al, 1991).
The expression of many drug metabolizing enzymes and cyto-
protective genes is subject to genetic polymorphism, resulting in
a diverse population distribution of alleles, often with signi¢-
cantly di¡erent levels of expression and catalytic activities (Wolf
and Smith, 1999;Wolf et al, 2000). For example, the GSTM1 and
GSTT1 genes are deleted in approximately 50% and 20% of the
Caucasian population, respectively, with a corresponding loss of
mRNA and protein expression (Seidegard et al, 1988; Pemble et al,
1994). Inheritance of these ‘‘null’’ GST alleles has been associated
with increased susceptibility to skin cancers (Lear et al, 2000) and
has been proposed as a determinant of cutaneous UVR erythemal
sensitivity (Kerb et al, 1997, 2002). Polymorphisms in NADPH-qui-
none oxidoreductase (NQO1), a £avoprotein that protects against
quinone-induced oxidative stress, have also been associated with
susceptibility to basal cell carcinoma (Clairmont et al, 1999), sug-
gesting that interindividual di¡erences in cutaneous cytoprotective
gene expression may be important determinants of individuality in
defense against environmental toxins.
Although there is increasing evidence that skin is metabolically
active, the majority of previous reports of cutaneous drug meta-
bolizing and cytoprotective gene expression have used cell cul-
ture or animal models and have not considered gene expression
in human skin in vivo. In addition, other in vivo studies of gene
expression have analyzed only a limited number of genes in small
numbers of subjects, making it di⁄cult to investigate interindivi-
dual di¡erences in expression, and to assess the relative contribu-
tion of individual genes to constitutive cutaneous expression.
Based on previous observations that speci¢c genes are inducible
by UVR, we hypothesized that other cutaneous drug metaboliz-
ing and cytoprotective genes may be expressed and regulated by
UVR and may be implicated in individual responses to photo-
therapy. Recent advances in analytical methods have allowed us
to perform a detailed characterization of drug metabolizing and
cytoprotective gene expression in human skin, using quantitative
‘‘Taqman’’ reverse transcription^PCR. We have therefore exam-
ined the constitutive expression of a variety of these genes and
investigated how gene expression is regulated by UVR, PUVA,
and in lesional psoriatic skin.
MATERIALS ANDMETHODS
Study participants Adults with stable untreated chronic plaque
psoriasis (median age 39 y (range 20^71), 21 males, eight females, skin
types I (n¼ 2), II (n¼15), III (n¼11), and V (n¼1)), about to commence
narrow band UVB (TL-01) phototherapy (n¼ 26) or oral PUVA (n¼ 3)
and a control group of healthy volunteers (n¼ 6, median age 41 y (range
36^54), two males, four females, skin types II (n¼ 2), III (n¼ 2), and IV
(n¼ 2)) were invited to participate in the study. Patients were excluded if
they had received UVB, PUVA, or systemic therapy for psoriasis within 6
mo prior to recruitment. No topical anti-psoriatic therapies (other than
emollients), and in particular, no tar-based preparations had been used on
buttock sites in the majority of patients (21 of 29) in the week prior to
recruitment. Four study participants (patients 6, 11, 14, and 15) had used
Eumovate (clobetasone butyrate) (GlaxoWellcome UK Ltd, Uxbridge,
UK) and an additional four participants (patients 34, 35, 41, and 43) had
used Dovonex (calcipotriol) (Leo Pharma, Buckinghamshire, UK) at
other body sites, but con¢rmed on questioning that these topical
preparations had not been applied to buttock sites. We are therefore
con¢dent that these treatments are extremely unlikely to have in£uenced
gene expression. Informed consent was obtained from all participants and
the study was approved by the Tayside Committee on Medical Research
Ethics. according to the Helsinki principles.
Prior to commencement of photo(chemo)therapy, irradiations were
performed on photoprotected buttock sites of patients with psoriasis
using either a solar simulator UVR source (150 W xenon arc lamp,
290^400 nm, 770 mW per cm2, 3.9^48 J per cm2) (n¼ 26), or a UVA dose
series (Waldmann F15W/T8, 320^400 nm, 5.7 mW per cm2, 0.5^7.9 J per
cm2) 2 h after ingestion of 8-methoxypsoralen (0.6 mg per kg;
Meladinine, Galderma, Buckinghamshire, UK) (n¼ 3). At 24 h after solar
simulator irradiation or 72 h after PUVA exposure, the minimal dose of
radiation required to cause a just perceptible erythema (the minimal
erythema dose (MED) or minimal phototoxic dose for PUVA (MPD))
was determined and biopsies performed. Full thickness (4 mm diameter)
punch biopsies were taken from: (1) an irradiated site (1^4MED or
3^4MPD); (2) adjacent untreated psoriatic plaque; and (3) adjacent
control site. Similarly, full thickness punch biopsies were taken from
photoprotected untreated buttock sites of a control group of healthy
volunteers (n¼ 6). All biopsy samples were immediately snap frozen in
liquid nitrogen and stored at ^701C prior to analysis.
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RNA preparation and cDNA synthesis Total RNA was extracted
from 4 mm diameter skin punch biopsies using Qiagen RNeasy (Qiagen,
Ltd, West Sussex, UK) spin columns, according to the manufacturer’s
instructions, with the addition of Proteinase K and DNase digestion steps.
RNA concentration and purity was determined spectrophotometrically by
measuring £uorescence at 260 nM and 280 nM. Total RNA (200 ng) was
reverse transcribed into cDNA in a total volume of 50 mL using PE
Applied Biosystems Taqman Reverse (Biosystems, Cheshire, UK)
transcription reagents according to the manufacturer’s instructions. One
microliter, corresponding to approximately 4 ng of input RNAwas used
in subsequent Taqman analysis.
Taqman quantitative real-time PCR analysis Sequence-speci¢c
primers and probes for Taqman quantitative PCR analysis of mRNA
expression were designed using PE Applied Biosystems Primer Express
software, according to the manufacturer’s protocol (please see table
published with the web version of this paper at http://www.
blackwellpublishing.com / products / journals / suppmat / JID / jid12354/
jid12354sm.htm). Each assay was designed such that the probe spanned an
intron/exon boundary to minimize the possibility of coamplifying
genomic DNA. PCR (1 (501C, 2 min, 951C, 10 min), 40 (921C, 15 s,
601C, 1 min) was performed in the presence of 0.6Taqman Universal
PCR Master Mix (PE Applied Biosystems), forward and reverse primers
and a sequence-speci¢c £uorescent probe. To ensure speci¢city of
ampli¢cation, all primer sequences were designed to include a minimum
of two unique nucleotides at the 30 end. Optimal probe and primer
concentrations were determined for each assay to ensure maximum
speci¢city. A panel of cDNA clones, representative of each gene of
interest, was used to con¢rm speci¢city of ampli¢cation. Real-time PCR
was performed on an ABI Prism 7700 Sequence Detector (‘‘Taqman’’),
where £uorescent output, measured as cycle threshold (Ct), was directly
proportional to input cDNA concentration. A Ct value of 40 was
interpreted as absence of gene expression, whereas Ct values in the range
35 to 40 were interpreted as being at the limit of detection of the
Taqman and were therefore not quantitatively analyzed. Input
cDNA concentrations were normalized to 18S ribosomal RNA, using
PE Applied Biosystems Ribosomal RNA control reagents.
Oligonucleotide primers were synthesized by MWG Biotech (MWG
Biotech, Milton Keynes, UK) and £uorescent Taqman probes by PE
Applied Biosystems.
Statistical analysis Triplicate measurements of skin mRNA expression
were made from each sample, and the arithmetic mean values taken. After
logarithmic transformation, within-subject di¡erences in mRNA
expression between ‘‘lesional’’ (irradiated or psoriatic plaque) and control
skin approximated a Gaussian distribution, and the paired t test was used
to compare values in lesional versus control skin. The arithmetic mean
di¡erences between lesional versus control skin log mRNA expression and
their con¢dence intervals (CI) become, when back-transformed, a ratio of
geometric mean mRNA expression values that represent a measure of
average fold induction. No statistical corrections were made for multiple
comparisons, but statistical signi¢cance was taken as po0.01, and
corresponding 99% CI are given. Stata (Intercooled Stata for Windows
version 7.0, Stata Corp., College Station, Texas, 2002) software was used.
Di¡erences in gene expression between healthy volunteers and psoriasis
patients were determined using unpaired t tests, where statistical
signi¢cance was taken as po0.05.
RESULTS
Constitutive cytoprotective gene expression in human
skin Quantitative real-time ‘‘Taqman’’ PCR analysis was used
to compare the expression of the major human glutathione-
dependent enzymes, P450 genes, drug transporters, and
cytoprotective genes in nonlesional skin taken from photo-
protected buttock sites in a representative panel of patients with
psoriasis (n¼10; Fig 1). GSTP1 was the most abundantly
expressed of the glutathione-dependent enzymes and was
expressed in all individuals (Fig 1A). In contrast, and in
agreement with our genotyping analysis (data not shown),
GSTM1 expression was detectable in only ¢ve of the 10
individuals examined. Similarly, although GSTT1 mRNA
expression was relatively low in human skin, there was complete
concordance between GSTT1 genotype and GSTT1 mRNA
expression (data not shown). GSTA4 mRNA expression was
consistently detected, in contrast to the a class GST isozymes
GSTA1 and GSTA2, which were not expressed. The catalytic or
‘‘heavy’’ subunit of g-glutamyl cysteine synthetase, the rate-
limiting enzyme in glutathione biosynthesis, was expressed
at low levels in all individuals, whereas GPx1 was more
abundantly expressed.
CYP1B1 was the most abundantly expressed P450 in human
skin (Fig 1B). CYP1A1 mRNA expression was also consistently
detected, but at much lower levels than CYP1B1, whereas the
closely related enzyme CYP1A2 was present only at the limit of
detection. In contrast, CYP2E1 was expressed at relatively high
levels. The most abundant P450 isozyme in human liver,
CYP3A4, was expressed only at very low levels in human skin
and at consistently lower levels than the closely related isozyme
CYP3A5, as was CYP2B6, whereas CYP2A6, CYP2C8,
CYP2C9, CYP2C18, and CYP2C19 were not detected. The
recently described extrahepatic P450, CYP2S1, was consistently
expressed, as was the P450 redox partner CPR (Smith et al,
2003).
MRP1 was the most highly expressed of the drug transporter
genes analyzed (Fig 1C). In contrast, MRP2 was expressed at
relatively low levels, as was the breast cancer resistance protein,
the expression of which has been described in various
extrahepatic tissues, including lung, placenta, and the
gastrointestinal tract (Maliepaard et al, 2001), but which has
not previously been shown to be expressed in human skin.
Expression of the organic anion transporter protein (OATP1)
was not detected, whereas the multidrug resistance protein
(MDR1) was expressed in all individuals.
Constitutive expression of the cytoprotective genes, COX-2,
HO-1, and NADPH-quinone reductase (NQO1) was also
detected in all individuals (Fig 1D). There were marked
interindividual di¡erences in the constitutive expression of many
of the genes studied, e.g., GSTP1, CYP1B1, CYP2E1, and MRP1
(Fig 1).
We selected a subset of genes, representative of the cutaneously
expressed glutathione-dependent enzymes, P450s, drug trans-
porters, and cytoprotective genes, to study the e¡ects of UVR
exposure on gene expression and to compare gene expression in
nonlesional and lesional psoriatic skin. Eleven genes (GPx-1,
GSTP1, GSTM1, CYP1B1, CYP2E1, CYP2S1, CYP3A5, CPR,
MRP1, COX-2, and HO-1) were selected either because they
were expressed at relatively high levels in human skin or because
they were known to be regulated by UVR (e.g., COX-2; Leong
et al, 1996).
Comparison of constitutive cytoprotective gene expression
in nonlesional skin from patients with psoriasis and healthy
volunteers We compared constitutive gene expression between
clinically ‘‘normal’’ nonlesional skin from patients with psoriasis
and skin obtained from healthy volunteers. There was a trend to
lower gene expression consistently in nonlesional buttock skin
from randomly selected psoriasis patients (n¼ 6) than in
photoprotected buttock skin from healthy volunteers (n¼ 6,
Table I), with the reduction in gene expression reaching
statistical signi¢cance (po0.05, unpaired t test) for GSTM1
(p¼ 0.04), CYP1B1 (p¼ 0.01), CYP2E1 (p¼ 0.02), CYP3A5
(p¼ 0.003), and HO-1 (p¼ 0.02).
Regulation of cytoprotective gene expression by UVR/
PUVA We compared gene expression in skin exposed to a
solar simulator at 1^4 MED UVRwith untreated skin (n¼ 26)
(Fig 2). Consistent with previous reports (Buckman et al, 1998),
COX-2 was markedly induced by UVR, with a ratio of
geometric mean induction of 3.63 (99% CI 2.07^6.36, po0.0001)
and a maximum induction of 22.6-fold (Fig 2A). More modest
inductions were seen for GSTP1 (1.90-fold, 99% CI 1.35^2.67,
po0.0001, maximum 16.25-fold, Fig 2B), CYP1B1 (1.48-fold,
99% CI 1.01^2.18, p¼ 0.009, maximum 5.41-fold, Fig 2C),
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Figure1. Constitutive cytoprotective gene ex-
pression in human skin. Quantitative real-time
reverse transcription^PCR was used to investigate
the constitutive expression of a variety of (A) glu-
tathione-dependent enzymes, (B) P450, (C) drug
transporters, and (D) stress response genes in nonle-
sional skin, taken from untreated photoprotected
buttock sites of a representative panel of the patients
with psoriasis (n¼10), as described in Materials and
Methods. Gene expression was normalized to 18S ri-
bosomal RNA to ensure equality of loading. All
samples were analyzed in triplicate. Data are pre-
sented as mean gene expression across the panel,
with the exception of GSTM1 and GSTT1 where
the data represent mean expression in GSTM1
(n¼ 5) and GSTT1 (n¼ 8) genotype-positive indi-
viduals. The standard deviation represents the ex-
tent of interindividual variation across the panel.
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CYP2E1 (1.13-fold, 99% CI 0.76^1.66, p¼ 0.40, maximum 5.13-
fold, Fig 2D), GPx-1 (1.61-fold, 99% CI 1.23^2.11, po0.0001,
maximum 4.95-fold, Fig 2E), and MRP1 (1.42-fold, 99% CI
1.03^1.96, maximum 6.59-fold, p¼ 0.0057, Fig 2F), whereas no
consistent induction was seen for CYP3A5, CPR, GSTM1, or
HO-1 (data not shown). CYP2S1 was also induced by UVR
(Smith et al, 2003). Interestingly, we observed induction of gene
expression for CYP1B1, CYP2E1, CYP2S1, CPR, GSTP1, GPx-1,
MRP1, HO-1, and COX-2 by PUVA in at least two of the three
PUVA patients studied (Fig 2).
Considerable interindividual variation in UVR inducibility
was seen for all the UVR-responsive genes examined. Doses of
UVR ranged from 1MED to 4MED UVR (2^3MED
in 20 of 26 patients; Fig 2), but there was no detectable
correlation between UVR dose and the degree of induction of
gene expression. In an attempt to identify a subset of gene
‘‘inducers’’ and ‘‘non-inducers’’ following UVR exposure, we
identi¢ed the ¢ve individuals with the highest and lowest fold
induction for each gene. Individuals 8, 19, 38, 40, and 41were the
most consistent UVR‘‘inducers’’, whereas individuals 5, 12, 16, 17,
and 18 consistently failed to show signi¢cant gene induction by
UVR (Fig 2).
Altered drug metabolizing and cytoprotective gene
expression in psoriatic plaque In order to determine
whether drug metabolizing or cytoprotective gene expression
was altered in lesional psoriatic skin, gene expression was
compared in biopsies taken from untreated lesional psoriatic
plaque and from adjacent clinically normal-appearing control
skin (n¼ 29) (Fig 3). HO-1 was consistently markedly induced
in psoriatic skin (10.19-fold induction, 99% CI 6.86^15.16,
po0.0001, maximum 49.68-fold; Fig 3A) as were GSTP1 (3.74-
fold, 99% CI 2.56^5.46, po0.0001, maximum 33.11-fold; Fig 3B),
CYP2E1 (3.64-fold, 99% CI 2.40^5.51, po0.0001, maximum
28.84-fold; Fig 3C), MRP1 (4.06-fold, 99% CI 2.98^5.53,
po0.0001, maximum 24.76-fold; Fig 3D), and CPR (3.42-fold,
99% CI 2.44^4.79, po0.0001, maximum 16.60-fold; Fig 3E).
GPx-1 (1.38-fold, 99% CI 1.06^1.79, p¼ 0.002, maximum 3.77-
fold), COX-2 (1.86-fold, 99% CI 1.29^2.70, p¼ 0.0001,
maximum 12.72-fold), and GSTM1 (1.64-fold, 99% CI 1.16^2.34,
p¼ 0.0008, maximum 2.66-fold) were also signi¢cantly induced
in psoriatic plaque. CYP2S1 was also markedly induced in
psoriatic skin (Smith et al, 2003). In contrast, signi¢cant decreases
in gene expression in psoriatic skin were observed for CYP1B1
(0.64-fold, 99% CI 0.45^0.93, p¼ 0.0025) and CYP3A5 (0.71-
fold, 99%CI 0.55^0.90, p¼ 0.0006). Again, we found signi¢cant
interindividual di¡erences in mRNA expression in psoriatic
plaques (Fig 3).
DISCUSSION
In addition to its function as a physical barrier, human skin is in-
creasingly recognized as a metabolically active organ. Skin is con-
stantly exposed to chemical and environmental stresses, such as
UVR, and it is therefore not surprising that it expresses a wide
variety of drug metabolizing enzymes and cytoprotective genes,
the expression of which is thought to have evolved as an adaptive
response to xenobiotic challenge (Nebert, 2000). Many previous
studies have shown that inherited interindividual di¡erences in
the hepatic expression of speci¢c drug metabolizing enzymes,
e.g., the P450 enzymes CYP2C9 and CYP2D6, are critical deter-
minants of systemic drug handling (Wolf and Smith, 1999;Wolf
et al, 2000) and recent evidence suggests that similar variation in
the cytoprotective GSTgenes GSTM1 and GSTTI in£uences sen-
sitivity to UVR (Kerb et al, 1997, 2002).
We found marked interindividual di¡erences in the constitutive
expression of the majority of the drug metabolizing and
cytoprotective genes analyzed, and identi¢ed signi¢cant di¡er-
ences in the expression of a number of genes in skin from healthy
volunteers compared with nonlesional skin from patients with
psoriasis. We additionally found marked di¡erences in gene ex-
pression comparing nonlesional and lesional psoriatic skin in pa-
tients and interindividual di¡erences in the cutaneous expression
of a number of genes in response to UVR, supporting our hy-
pothesis that cutaneous drug metabolizing and cytoprotective
gene expression can be regulated in response to UVR and PUVA.
There have now been several reports in which P450, GST, and
other cytoprotective genes have been identi¢ed in human skin
(e.g., Katiyar et al, 2000; Baron et al, 2001); however, the majority
of studies considered only a limited number of genes or were
performed in vitro and are therefore not necessarily representative
of gene expression in vivo. A major advantage of our quantitative
reverse transcription^PCR approach is that it has allowed us to
compare and contrast the expression of a wide variety of genes
both within and between individuals. In previous studies using
northern or Western blotting techniques or immunohistochem-
ical analysis, for example, it has not always been possible to un-
iquely identify individual genes, particularly when investigating
the expression of speci¢c P450s or GSTs, which are members of
extensive, highly homologous gene families. The use of reverse
transcription^PCR, in the presence of a £uorescent gene-speci¢c
probe, not only provides us with an extremely sensitive approach,
but allows us to be con¢dent that our analysis is isozyme speci¢c.
Consistent with their role in cellular defense against ROS, the
glutathione-dependent enzymes were the most abundantly ex-
pressed of the genes examined (Fig 1), with the p-class GST iso-
zyme GSTP1 expressed at the highest level. The use of gene-
speci¢c Taqman probes allowed us to identify the a-class enzyme
Table I Comparison of constituitive cytoprotective gene expression in non-lesional skin from patients with psoriasis and
healthy volunteers
Gene
Average gene expression in healthy
volunteers (arbitrary units7SD)
Average gene expression in psoriasis
patients (arbitrary units7SD)
Reduction in gene expression in
psoriasis patients (%)
p-value
(unpaired t-test)
CYP1B1 87.6724.9 50.1715.3 43 0.01
CYP2E1 23.276.8 12.377.2 47 0.02
CYP2S1 8.573.0 7.071.7 18 0.33
CYP3A5 21.575.2 11.473.1 47 0.003
CPR 39.8711.3 25.7713.2 35 0.08
GSTM1 333.87148.9 135.5751.7 59 0.04
GSTP1 366.07129.4 254.57113.4 33 0.15
GPx-1 1026.07263.0 810.57333.3 21 0.25
HO-1 27.4714.4 6.872.7 75 0.02
COX-2 4.272.4 3.171.3 26 0.33
MRP1 90.5719.8 70.8722.3 22 0.14
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Figure 2. Induction of gene expression by UVR. Changes in gene expression for: (A) COX-2; (B) GSTP1; (C) CYP1B1; (D)
CYP2E1; (E) GPx-1; and (F) MRP1 in UVR irradiated skin (o 2MED, dark blue bars; 2^3MED, light blue bars; 43MED, green bars)
compared with control skin in the same patients are shown. Expression in PUVA-treated skin is also shown (red bars). All gene expression was
normalized to 18S ribosomal RNA to ensure equality of loading and all samples were analyzed in triplicate. Each bar represents data derived from a single
individual.
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expressed in human skin as GSTA4, in agreement with immuno-
histochemical analysis of GSTA4 expression in several extrahepa-
tic tissues (Desmots et al, 2001). GSTA1 and GSTA2 were not
constitutively expressed in human skin or inducible by UVR.
As expected, we found complete concordance between lack of
cutaneous expression of GSTM1 and GSTT1 and inheritance of
the null GST alleles (Seidegard et al, 1988; Pemble et al, 1994).
In contrast to human liver, where the CYP3A and CYP2C en-
zymes are the most abundantly expressed P450 isozymes (Shima-
da et al, 1994), and in agreement with previous studies in other
extrahepatic tissues (Spink et al, 1994; Murray et al, 1997), we
found CYP1B1 to be the most abundantly expressed P450 in hu-
man skin. Contrary to the ¢ndings of Katiyar et al (2000) and
Baron et al (2001) who reported similar levels of CYP1A1 and
CYP1B1 expression in human epidermal keratinocytes, we found
CYP1A1 to be constitutively expressed at very low levels in hu-
man skin in vivo. Cutaneous CYP1A1 or ‘‘aryl hydrocarbon hy-
droxylase’’ has been shown in human skin and in animal models
Figure 3. Induction of gene expression in psoriatic plaque. Changes in gene expression for: (A) HO-1; (B) GSTP1; (C) CYP2E1; (D) MRP1; (E)
CPR; and (F) GPx-1 in lesional psoriatic skin compared with control skin in the same patients are shown. All gene expression was normalized to 18S
ribosomal RNA to ensure equality of loading and all samples were analyzed in triplicate. Each bar represents data derived from a single individual.
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to be inducible by coal tar, a rich source of polycyclic aromatic
hydrocarbons (Bickers and Kappas, 1978; Li et al, 1995). We have
independently shown that topical coal tar induces CYP1A1 ex-
pression in human skin and have shown very similar e¡ects for
CYP1B1 (unpublished data). Our CYP1A1 and CYP1B1 RNA
expression data suggest that previous reports of constitutive aryl
hydrocarbon hydroxylase activity may in fact be more attributa-
ble to constitutive CYP1B1 rather than CYP1A1 expression. The
cutaneous expression of CYP2E1 was particularly interesting, as
CYP2E1 has previously been implicated in defense against ROS
(Sun and Sun, 2001). CYP2E1 mRNA expression was also de-
tected in human skin by Baron et al (2001) using reverse tran-
scription^PCR. Consistent with our data, these authors also
reported the constitutive expression of CYP2B6 and CYP3A5.
Whereas we found CYP3A5 to be present in all individuals
tested, CYP2B6 expression was variable and present only at the
limit of detection in the majority of individuals. We recently
identi¢ed the cutaneous expression of CYP2S1, a novel P450,
which is predominantly expressed in extrahepatic tissues (Rylan-
der et al, 2001) and the presence of CPR, the redox partner, and
electron donor to all P450s, suggesting that human skin has the
ability to support functional P450 expression (Smith et al, 2003).
Drug transporter proteins function as membrane-associated
adenosine triphosphate-dependent e¥ux pumps, which protect
the cell from xenobiotic challenge (Litman et al, 2001). Increased
expression of MDR1, the gene encoding P-glycoprotein, has
been associated with the development of many drug-resistant
cancers through active extrusion of drug from the cell (Gottes-
man et al, 2002). MDR1 or P-glycoprotein expression has pre-
viously been demonstrated in human skin (Baron et al, 2001),
although its function is unclear. The multidrug resistance asso-
ciated protein MRP1 is involved in the active transport of glu-
tathione conjugates (Keppler et al, 1997). Consistent with our
¢nding that the glutathione-dependent enzymes are expressed at
high levels in human skin, we also found relatively high levels of
MRP1 expression.
A number of cytoprotective genes are thought to have evolved
to protect the cell from oxidative challenge, following exposure
to ROS (Afaq and Mukhtar, 2001).We found the constitutive ex-
pression of the cytoprotective genes COX-2, HO-1, and quinone
reductase (NQO1) to be relatively low in comparison with the
glutathione-dependent enzymes, P450s, and drug transporters
(Fig 1).
Comparison of constitutive gene expression in photoprotected
skin from healthy volunteers and patients with psoriasis pro-
duced interesting results, with a trend to reduced expression of
all the genes examined in clinically una¡ected skin of psoriasis
patients and signi¢cant reduction in expression of a subset of
genes, notably CYP1B1, CYP2E1, and CYP3A5, reduced expres-
sion of which has previously been reported in response to in£am-
matory mediators (Morgan, 1997, 2001). Our data suggest that
there may be fundamental di¡erences in metabolizing and detox-
ifying capacity between patients with psoriasis and healthy vo-
lunteers, although clearly these observations will need to be
substantiated in a larger study.
The e¡ects of UVR on drug metabolizing and cytoprotective
gene expression were, in general, less pronounced than the
changes seen in psoriatic plaque expression (Figs 2 and 3). Con-
sistent with previous reports (Buckmann et al, 1998), we saw sig-
ni¢cant induction of COX-2 gene expression in response to
UVR and PUVA, although there were marked interindividual
di¡erences in response (Fig 2). In contrast to the results of Katiyar
et al (2000) who reported UVB-mediated induction of both
CYP1A1 and CYP1B1 gene expression, we found signi¢cant
CYP1B1 induction in only a subset of individuals and saw no
consistent induction of CYP1A1, the constitutive expression of
which was seen only at the limit of detection in all individuals
tested. UVR exposure induced the expression of a number of
other drug metabolizing and cytoprotective genes in some indi-
viduals, including CYP2E1, GSTP1, GPx-1, and MRP1, suggest-
ing that there may be common mechanisms through which these
genes respond to oxidative stress. A number of transcription fac-
tors including activator protein-1 and nuclear factor-kB have
been shown to mediate the e¡ects of both in£ammatory media-
tors and ROS on gene transcription (Buerle and Henkel, 1994;
Karin et al, 1997). Activator protein-1 binds c-fos/c-jun heterodi-
mers, both of which have been shown to be expressed in the skin
(Welter and Eckert, 1995) and, through increased transcription of
c-fos and c-jun, is known to mediate induction of the cutaneous
expression of genes in response to a variety of extracellular stimu-
li, including UVR (Fisher et al, 1997).
The expression of many of the genes examined was markedly
increased in lesional psoriatic skin (Fig 2). The greatest increase in
gene expression was seen for HO-1, increased transcription of
which occurs as an adaptive response to provide cellular defense
against oxidative stress (Applegate et al, 1991), and GSTP1, the ex-
pression of which has previously been shown to be induced in
response to cellular hyperproliferation (Satoh et al, 1985). Consis-
tent with our observations, increased HO-1 expression has pre-
viously been reported in lesional psoriatic skin (Hanselmann
et al, 2001) and GSTP1 expression has been shown to be increased
in psoriatic scale (Aceto et al, 1992). Signi¢cant and previously un-
reported increases in gene expression in psoriatic plaques were
observed for CYP2E1, CPR, and MRP1, suggesting that there
is a global upregulation of drug metabolizing potential in lesional
psoriatic skin. In light of these ¢ndings, it is of interest that peri-
lesional or nonlesional skin of patients with psoriasis is more sus-
ceptible than lesional skin to irritancy following treatment with
coal tar or dithranol and is more likely to develop phototherapy-
induced erythema. There were clear interindividual di¡erences in
the level of constitutive expression and inducibility in psoriatic
plaques of each of the enzymes analyzed. Further studies are re-
quired to determine whether these di¡erences are also re£ected in
induction of protein expression and to investigate whether indi-
viduality in gene expression is of clinical relevance.
These data demonstrate, for the ¢rst time, that there are
marked interindividual di¡erences in the constitutive expression
of a variety of drug metabolizing and cytoprotective enzymes in
human skin, in psoriatic plaques and in response to UVR and
PUVA. There is unequivocal evidence that individuality in hepa-
tic drug metabolizing enzyme and cytoprotective gene expres-
sion is a determinant of the adaptive response to systemic drugs
and environmental toxins. At present, however, we have no clin-
ical predictors of response to phototherapy and further studies are
therefore needed to investigate the potential role of these genes as
phenotypic markers of treatment response.
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